Kinetic Analysis Of Antibodies From Different Cultured Media

By David Ho, Tom Fletcher, and Jessie H.T. Ni

The Octet QKe platform is evaluated to establish an analytical method for assessing the effects of media condition on the quality and activity of cultured antibodies. the affinity and kinetics of monoclonal antibodies produced from a hybridoma cell line cultured in two different types of medium were measured. With this method, the authors were able to measure the intermolecular binding interactions between the antibodies and targeted protein. the qualitative measurement, in addition to cell growth and titer production, can be useful to further develop and select essential media components to improve product functionality to a cell line.

Traditionally, the culture growth and biologic titer production have been used exclusively to evaluate the performances of cell lines and the culture environment, such as media development optimization. Several analysis approaches have evolved to characterize the quality of the biologics produced, (e.g., antibodies have been of great interest due to fast growth of bio similar and bio better business). These approaches focus on determining the antibody quality from information related to the antibody purity, charge variant, glycan, and kinetics. In thisstudy,the authors evaluate the Octet QKe plat - form to establish an analyti - cal method to asses media condition effect  on the  quality and activity of cultured antibodies by measuring the affinity and kinetics of monoclonal antibodies (mAbs) produced from a hybridoma cell line cultured in two different types of medium. With this method, the intermolecular binding interactions between the antibodies and targeted protein can be measured to identify an approach to the activity of interest, such as anin vivo the rapeutic response. The qualitative measurement, in addition to cell growth and titer production, can be useful to further develop and select essential media components to improve product functionality to a cell line.

©BioPharm International July 2013